Upcoming Rare Genomics Events, Conferences and Speaking Appearances

Invitation to Upcoming Podcast Discussion
RG/RareShare Ask the Experts LGLL Podcast Series IV

Rare Genomics Institute and RareShare are proud to invite you to the upcoming podcast discussing:
Living with Large Granular Lymphocytic Leukaemia (LGLL) – A Clinical & Research Perspective-
Featuring

Dr Jaroslaw P. Maciejewski & Dr Thomas P Loughran

DATE: 11/18/2016

TIME: 9:00 AM-10:00 AM EST (6:00 AM-7:00 AM PST, 1:00 PM-2:00 PM GMT)
Podcast Dial in Link:  https://www.youtube.com/watch?v=pqp8wwlxMOU

  • Are you interested in learning about recent clinical and research developments and available treatment options for LGLL?

  • What questions would you ask about symptom management of LGLL if you had the experts at hand?

  • Do you have any burning questions you have wanted to ask about LGLL but haven’t had the chance to?

Here is that chance!
The first 25 minute segment will feature medical scientists/clinicians discussing the latest developments in LGLL regarding genomics and biotechnology research, while the remaining 20 minutes the guest speakers will answer your questions/concerns/issues

Here is your chance to ask any question you may have about LGLL:

Submit your question(s) NOW by clicking this form (RareShare LGLL Podcast Registration Form) and/or register to attend the program.**

Example questions are:

  • What are the acute symptoms of LGLL?

  • What can I expect for my spleen and B-Symptoms because I have LGLL? Or,

  • What kinds of treatments are available to manage my Rheumtoid Arthritis and Neutropenia due to LGLL?

Register below to reserve your spot in the call!
PS. If you cannot participate but would like to ask our experts any questions, please submit them below. The transcript and recording will be posted on the homepage of Rare Genomics and RareShare LGLL Community after the live Q&A.

 Meet our Panel of Expert

maciejewski-jaroslaw.jpg

Dr Jaroslaw P. Maciejewski, MD, PhD, FACP,
Staff Physician in the Cleveland Clinic Department of Hematologic Oncology and Blood Disorders

Dr Maciejewski is board certified in hematology and internal medicine. He is also Chairman of the Department of Translational Hematology and Oncology Research at the Taussig Cancer Institute and has an academic rank of Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.  He joined Cleveland Clinic in 2001 as Staff Physician and Section Head of Experimental Hematology. In January 2009, Dr. Maciejewski was appointed Chairman of the newly created Department of Translational Hematology and Oncology Research at the Taussig Cancer Institute.
Dr. Maciejewski attended medical school at the Medical School Charite, Humboldt University, Berlin, Germany receiving his medical degree and doctorate from the Institute for Medical Immunology at Humboldt University Medical School. He completed his internal medicine residency at the University of Nevada, School of Medicine in Reno, NV and Hematology Fellowship at the National Institutes of Health Medical Center, Bethesda, MD. He completed his postdoctoral research fellowship at the Hematology Branch of the National Heart, Lung and Blood Institute (NHLBI) in Bethesda, MD where he later served as Staff Scientist.
Research Expertise
His clinical areas of expertise include bone marrow failure syndromes (including aplastic anemia, myelodysplastic syndrome, large granular lymphocyte leukemia, paroxysmal nocturnal hemoglobinuria), and myeloid malignancies. His research deals with the molecular pathogenesis of these disorders and deals with various specific aspects of stem cell biology, genetics, cytogenetics and immunobiology. He has developed multiple whole genome scanning technologies for laboratory and diagnostic use, including SNP-arrays, methylation arrays and viral chips.
Dr. Maciejewski has a distinguished track record in research relating to the hematology and pathophysiology of hematologic diseases including bone marrow failure syndromes. His extensive list of over 150 publications demonstrates his success as an accomplished translational physician-scientist. As Principal Investigator, Dr. Maciejewski has acquired notable grant funding from federal, foundation and industry sponsors since joining Cleveland Clinic in 2001. He received a $1.9 million grant award from the National Institutes of Health’s Transformative R01 program to support research related to whether viruses could be the cause of certain types of bone marrow cancers and other blood disorders. Mr Maciejewski also leads the Cleveland Clinic Bone Marrow Failure Program that conducts various clinical trials based on investigator-initiated protocols involving the application of targeted immune therapies. He is the recipient of numerous awards and honors such as American Society of Clinical Investigation, America's Best Doctors, Fellow in FACP since 7/1/09 from the Ohio Chapter
 

LoughranT.png

Dr. Thomas P Loughran, MD
Director of the University of Virginia Cancer Center, F. Palmer Weber-Smithfield Foods Professor of Oncology Research and Professor of Medicine

From July 2003 to August 2013, he served as the founding director of the Penn State Hershey Cancer Institute and Professor of Medicine at the Penn State College of Medicine. He previously served as program leader of hematologic malignancies at the H. Lee Moffitt Cancer Center and Research Institute at the University of South Florida, associate director of the Bone Marrow Transplant Program at SUNY Health Science Center, and chief of hematology at the Syracuse Veteran's Affairs Medical Center in Syracuse, N.Y. He completed his fellowship in medical oncology at the Fred Hutchinson Cancer Research Center under direction of Nobel Laureate, Dr. E.D. Thomas and remained on faculty there for seven years. Dr Loughran attended Hahnemann Medical School for his MD
Research Description
Dr. Loughran’s career as a physician-scientist has been a testament to translational research, with clinical observations leading to discoveries in the laboratory, and laboratory research contributing to improved clinical treatments. He was instrumental in the discovery of large granular lymphocyte (LGL) leukemia (Ann Intern Med 102:169, 1985), and is considered the worldwide expert in this disease. He has published numerous articles in high impact peer-reviewed journals including The New England Journal of Medicine, Annals of Internal Medicine, Lancet, Journal of Clinical Investigation, Journal of Clinical Oncology, and Blood.
“His current research includes:
an R01 grant from the NIH’s National Cancer Institute to identify and characterize the LGL leukemia virus and understand how it might cause leukemia;
an NCI RO1 grant to study the pathogenesis of LGL leukemia;
a translational research grant from the Leukemia & Lymphoma Society to investigate new treatments for LGL leukemia;
a program project grant from the NCI aimed at developing new therapeutics for acute myelogenous leukemia”



Sign-in here to reserve your spot for the Podcast!